Skip to main content
Equibles
TCRX logo

TCRX · TScan Therapeutics, Inc. · Metrics

Track TCRX — free

Use TCRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TCRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.22 +0.01 (+6.57%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“However, substantial doubt about the Company's ability to continue as a going concern exists. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Therefore, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”
View the 10-Q filed Aug 12, 2026
Market Cap
$14.25M
Shares
67.78M
Volume · Oct 20 559.56K Avg daily vol (3M) 763.51K

TCRX metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.22
Market cap
$14.25M

Price action

20 metrics
Price change (1W)
-11.6%
Price change (30D)
-36.4%
Price change (3M)
-77.3%
Price change (6M)
-85.3%
Price change (YTD)
-79.0%
Price change (1Y)
-91.5%
Trailing year
Price change (5Y)
-97.1%
52-week high
$2.52
52-week low
$0.21
Change from 52-week high
-91.7%
Change from 52-week low
+0.0%
Annualized volatility
99.4%
Annualized volatility (3M)
115.0%
Beta
1.7
RSI (14D)
26.3
Price vs SMA 50
-54.5%
Price vs SMA 200
-76.5%
Avg volume (3M)
759,508
Relative volume
0.5
Average dollar volume
$343,125

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
67.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-7.3×
EV / EBITDA
—
EV / EBIT
—
P / sales
2.2×
reciprocal yield 45.4%
P / book
0.2
reciprocal yield 440.8%
FCF yield
-756.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-751.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-3.9×
EV / revenue historical average (5Y)
-3.9×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-05-06

Profitability

9 metrics
Gross margin
—
Operating margin
-1,695.1%
Trailing 12 months
Net margin
-1,655.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$120.54M
Net income (TTM)
−$117.71M
Trailing 12 months
Diluted EPS (TTM)
$-0.91
FCF margin
-1,665.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.05
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.93
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.91
Operating cash flow per diluted share (TTM)
$-0.90
Free cash flow per diluted share (TTM)
$-0.91
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$0.75
Stock compensation per diluted share (TTM)
$0.08
Book value per share
$-42.28

Growth

11 metrics
Revenue growth YoY
-65.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.11M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.2%
Year over year · more shares
Revenue CAGR (3Y)
-8.6%
Revenue CAGR (5Y)
+56.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-170.6%
Return on assets
-68.7%
Debt / equity
0.5
Current ratio
3.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$118.44M
Quick ratio
3.4
Interest coverage
-43.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$67.38M
Latest balance sheet
Cash & equivalents
$100.16M
Total assets
$171.45M
Total debt
$32.78M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$116.28M
Capital expenditures (TTM)
$2.16M
R&D (TTM)
$97.03M
SG&A (TTM)
—
Stock compensation (TTM)
$9.84M
R&D / revenue
1,364.6%
Stock compensation / revenue
138.4%

Ownership (13F)

9 metrics
13F filers
60
13F filer change QoQ
0
Institutional ownership
52.9%
Conviction holders (share of 13F filers)
5.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+18.7%
Holder tenure
10.6
Price vs estimated holder cost
-63.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.1%

Short interest

3 metrics
Short interest
3.7%
Latest settlement · 3.3 days to cover
Days to cover
3.3d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1783328 CUSIP 89854M101 13F (30d) 1 filings 1 filers Visit website Investor relations